Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 6 (June)

1. Ease of oral administration and owner-perceived acceptability of triglyceride oil, dissolving thin film strip, and gelatin capsule formulations to healthy cats.
   Am J Vet Res, 71(6): 610-4. [Abstract] [Full-text]
2. Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis.
   J Cereb Blood Flow Metab, 30(6): 1214-25. [Abstract] [Full-text]
3. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
   J Cereb Blood Flow Metab, 30(6): 1137-46. [Abstract] [Full-text]
4. Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma.
   J Neurosurg Pediatr, 5(6): 615-21. [Abstract] [Full-text]
5. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
   Cancer Res, 70(11): 4687-97. [Abstract] [Full-text]
6. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.
   Cancer Res, 70(11): 4520-7. [Abstract] [Full-text]
7. A unique experiment in neurological surgery: intracerebral injection of antitoxin for tetanus.
   J Neurosurg, 112(6): 1318-21. [Abstract] [Full-text]
8. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
   N Engl J Med, 362(22): 2053-65. [Abstract] [Full-text]
9. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA.
   J Infect Dis, 202(1): 161-70. [Abstract] [Full-text]
10. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy.
    J Infect Dis, 202(1): 156-60. [Abstract] [Full-text]
11. Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
    Anticancer Drugs, 21(6): 662-8. [Abstract] [Full-text]
12. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
    Anticancer Drugs, 21(6): 651-5. [Abstract] [Full-text]
13. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study.
    Anticancer Drugs, 21(6): 656-61. [Abstract] [Full-text]
14. Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy.
    Clin Infect Dis, 51(1): 93-8. [Abstract] [Full-text]
15. Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
    Cancer Invest, 28(6): 654-60. [Abstract] [Full-text]
16. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
    Lancet Oncol, 11(6): 561-70. [Abstract] [Full-text]
17. Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells.
    Cancer Invest, 28(6): 629-34. [Abstract] [Full-text]
18. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
    Cancer Invest, 28(6): 623-8. [Abstract] [Full-text]
19. Analysis application in biological field and prediction of human diseases with dual luminescence molecular of 3.5-generations polyamidoamine dendrimers-porphyrin.
    Spectrochim Acta A Mol Biomol Spectrosc, 76(5): 439-45. [Abstract] [Full-text]
20. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    Am J Clin Oncol, 33(3): 307-13. [Abstract] [Full-text]
21. Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma.
    Hematol Oncol, 28(2): 68-74. [Abstract] [Full-text]
22. A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
    Am J Clin Oncol, 33(3): 242-5. [Abstract] [Full-text]
23. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
    Am J Clin Oncol, 33(3): 257-61. [Abstract] [Full-text]
24. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Am J Clin Oncol, 33(3): 246-50. [Abstract] [Full-text]
25. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
    Am J Clin Oncol, 33(3): 233-7. [Abstract] [Full-text]
26. Higher order structure of short collagen model peptides attached to dendrimers and linear polymers.
    Biopolymers, 93(7): 640-8. [Abstract] [Full-text]
27. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
    Br J Cancer, 102(12): 1699-706. [Abstract] [Full-text]
28. Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells.
    Biochem Pharmacol, 80(3): 325-34. [Abstract] [Full-text]
29. Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR).
    Biochem Pharmacol, 80(3): 297-307. [Abstract] [Full-text]
30. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways.
    Cancer Lett, 294(2): 147-58. [Abstract] [Full-text]
31. Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways.
    Leuk Res, 34(8): 1057-63. [Abstract] [Full-text]
32. Reactive oxygen species (ROS) induced cytokine production and cytotoxicity of PAMAM dendrimers in J774A.1 cells.
    Toxicol Appl Pharmacol, 246(1): 91-9. [Abstract] [Full-text]
33. A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery.
    Toxicol Appl Pharmacol, 246(1): 83-90. [Abstract] [Full-text]
34. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Gynecol Oncol, 118(1): 52-7. [Abstract] [Full-text]
35. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
    Gynecol Oncol, 118(1): 47-51. [Abstract] [Full-text]
36. Long-term gonadal hormone treatment and endogenous neurogenesis in the dentate gyrus of the adult female monkey.
    Exp Neurol, 224(1): 252-7. [Abstract] [Full-text]
37. Estrogen effects on pain sensitivity and neuropeptide expression in rat sensory neurons.
    Exp Neurol, 224(1): 163-9. [Abstract] [Full-text]
38. Efficacy of intra-lesional alcohol injection as alternative and/or complementary treatment of vascular malformations: a systematic review.
    J Plast Reconstr Aesthet Surg, 63(7): 1071-9. [Abstract] [Full-text]
39. Antiretroviral therapy and reproductive life projects: mitigating the stigma of AIDS in Nigeria.
    Soc Sci Med, 71(2): 345-52. [Abstract] [Full-text]
40. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors.
    J Urol, 184(1): 168-73. [Abstract] [Full-text]
41. Biomaterial-based technologies for brain anti-cancer therapeutics and imaging.
    Biochim Biophys Acta, 1806(1): 96-107. [Abstract] [Full-text]
42. Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy.
    Cell Prolif, 43(3): 262-74. [Abstract] [Full-text]
43. Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
    J Natl Cancer Inst, 102(12): E1. [Abstract] [Full-text]
44. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.
    J Natl Cancer Inst, 102(12): 859-65. [Abstract] [Full-text]
45. Butyrate enemas improve intestinal anastomotic strength in a rat model.
    Dis Colon Rectum, 53(7): 1069-75. [Abstract] [Full-text]
46. Drug errors: consequences, mechanisms, and avoidance.
    Br J Anaesth, 105(1): 76-82. [Abstract] [Full-text]
47. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
    Cancer Chemother Pharmacol, 66(3): 597-603. [Abstract] [Full-text]
48. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Cancer Chemother Pharmacol, 66(3): 559-66. [Abstract] [Full-text]
49. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
    Cancer Chemother Pharmacol, 66(3): 441-8. [Abstract] [Full-text]
50. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
    Cancer Chemother Pharmacol, 66(3): 547-58. [Abstract] [Full-text]
51. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Cancer Chemother Pharmacol, 66(3): 425-31. [Abstract] [Full-text]
52. Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
    Cancer Chemother Pharmacol, 66(3): 575-83. [Abstract] [Full-text]
53. Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress.
    Cancer Chemother Pharmacol, 66(3): 517-26. [Abstract] [Full-text]
54. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
    Cancer Chemother Pharmacol, 66(3): 527-34. [Abstract] [Full-text]
55. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
    Cancer Chemother Pharmacol, 66(3): 455-66. [Abstract] [Full-text]
56. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 66(3): 493-500. [Abstract] [Full-text]
57. Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy.
    Cancer Chemother Pharmacol, 66(3): 501-6. [Abstract] [Full-text]
58. Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol, 66(3): 449-53. [Abstract] [Full-text]
59. Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
    N Engl J Med, 362(24): 2282-94. [Abstract] [Full-text]
60. Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
    Tumour Biol, 31(4): 333-40. [Abstract] [Full-text]
61. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
    Tumour Biol, 31(4): 351-7. [Abstract] [Full-text]
62. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Trop Doct, 40(3): 167-8. [Abstract] [Full-text]
63. The use of computer software for planning care in a resource-scarce setting.
    Trop Doct, 40(3): 152-5. [Abstract] [Full-text]
64. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
    J Clin Oncol, 28(18): 2989-95. [Abstract] [Full-text]
65. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
    J Clin Oncol, 28(18): 3028-34. [Abstract] [Full-text]
66. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
    J Clin Oncol, 28(18): 2958-65. [Abstract] [Full-text]
67. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
    J Clin Oncol, 28(18): 2982-8. [Abstract] [Full-text]
68. Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
    J Clin Oncol, 28(18): 2974-81. [Abstract] [Full-text]
69. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    J Clin Oncol, 28(18): 3069-75. [Abstract] [Full-text]
70. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    J Clin Oncol, 28(18): 2966-73. [Abstract] [Full-text]
71. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
    J Clin Oncol, 28(18): 2947-51. [Abstract] [Full-text]
72. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
    J Clin Oncol, 28(18): 3035-41. [Abstract] [Full-text]
73. Absolute ethanol sclerotherapy for venous malformations in the face and neck.
    J Oral Maxillofac Surg, 68(7): 1622-7. [Abstract] [Full-text]
74. Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
    Ann Hematol, 89(8): 783-7. [Abstract] [Full-text]
75. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.
    J Cancer Res Clin Oncol, 136(8): 1193-9. [Abstract] [Full-text]
76. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
    J Cancer Res Clin Oncol, 136(8): 1135-42. [Abstract] [Full-text]
77. Efficacy of a methyl ester of 5-aminolevulinic acid in photodynamic therapy for ovarian cancers.
    J Cancer Res Clin Oncol, 136(8): 1143-50. [Abstract] [Full-text]
78. Celecoxib increases retinoid sensitivity in human colon cancer cell lines.
    Cell Mol Biol Lett, 15(3): 440-50. [Abstract] [Full-text]
79. Bimolecular fluorescence complementation (BiFC) assay for protein-protein interaction in onion cells using the helios gene gun.
    J Vis Exp. [Abstract] [Full-text]
80. Complications of cervical transforaminal epidural steroid injections.
    Am J Phys Med Rehabil, 89(7): 601-7. [Abstract] [Full-text]
81. Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.
    BMC Cancer, 10: 257. [Abstract] [Full-text]
82. Nucleolar changes and fibrillarin redistribution following apatone treatment of human bladder carcinoma cells.
    J Histochem Cytochem, 58(7): 635-51. [Abstract] [Full-text]
83. Menopause, postmenopausal hormone use and risk of incident gout.
    Ann Rheum Dis, 69(7): 1305-9. [Abstract] [Full-text]
84. Tracking of antibody reduction fragments by capillary gel electrophoresis during the coupling to microparticles surface.
    J Pharm Biomed Anal, 53(2): 172-8. [Abstract] [Full-text]
85. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    N Engl J Med, 362(25): 2380-8. [Abstract] [Full-text]
86. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study.
    Cancer, 116(13): 3102-11. [Abstract] [Full-text]
87. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy.
    Cancer, 116(13): 3189-94. [Abstract] [Full-text]
88. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Cancer, 116(13): 3143-51. [Abstract] [Full-text]
89. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
    Cancer, 116(13): 3294-303. [Abstract] [Full-text]
90. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency.
    Eur J Endocrinol, 163(1): 15-20. [Abstract] [Full-text]
91. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
    Blood, 115(25): 5241-8. [Abstract] [Full-text]
92. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
    Blood, 115(25): 5137-46. [Abstract] [Full-text]
93. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
    Apoptosis, 15(7): 805-13. [Abstract] [Full-text]
94. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial.
    Am J Epidemiol, 172(1): 107-15. [Abstract] [Full-text]
95. Safety of performing CT angiography in stroke patients treated with intravenous thrombolysis.
    J Neurol Neurosurg Psychiatry, 81(7): 783-7. [Abstract] [Full-text]
96. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
    Am J Hematol, 85(7): 499-501. [Abstract] [Full-text]
97. Off-label thrombolysis is not associated with poor outcome in patients with stroke.
    Stroke, 41(7): 1450-8. [Abstract] [Full-text]
98. The "golden hour" and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset.
    Stroke, 41(7): 1431-9. [Abstract] [Full-text]
99. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
    J Clin Oncol, 28(19): 3191-8. [Abstract] [Full-text]
100. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
     J Clin Oncol, 28(19): 3160-6. [Abstract] [Full-text]
101. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
     J Clin Oncol, 28(19): 3138-45. [Abstract] [Full-text]
102. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
     J Clin Oncol, 28(19): 3107-14. [Abstract] [Full-text]
103. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
     Br J Cancer, 103(1): 12-7. [Abstract] [Full-text]
104. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
     Jpn J Clin Oncol, 40(7): 634-8. [Abstract] [Full-text]
105. A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606).
     Br J Cancer, 103(1): 6-11. [Abstract] [Full-text]
106. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs.
     Br J Cancer, 103(1): 36-42. [Abstract] [Full-text]
107. Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports.
     Jpn J Clin Oncol, 40(7): 694-8. [Abstract] [Full-text]
108. Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis.
     Jpn J Clin Oncol, 40(7): 684-9. [Abstract] [Full-text]
109. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
     Jpn J Clin Oncol, 40(7): 699-701. [Abstract] [Full-text]
110. Adjuvant chemoradiation therapy in gallbladder cancer.
     J Surg Oncol, 102(1): 87-93. [Abstract] [Full-text]
111. A Whitacre-type spinal needle does not prevent intravascular injection during cervical nerve root injections.
     South Med J, 103(7): 679-82. [Abstract] [Full-text]
112. Survival of individuals with cerebral palsy receiving continuous intrathecal baclofen treatment: a matched-cohort study.
     Dev Med Child Neurol, 52(7): 672-6. [Abstract] [Full-text]
113. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.
     AIDS, 24(11): 1709-16. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.